Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
10.1249/MSS.0000000000000336 103
Weight Loss: Whats Different
This is a pivotal moment for the food industry. Noting that 12% of the US population has tried the drugs, with 6% actively using them, Harold Schmitz at VC firm The March Group said the Ozempic era is helping to rejuvenate the foodtech space, which is now very much alive. Courtney McHugh, chief commercial officer at Amplifye, a UC Davis spinout with an enzyme that helps the body digest protein more effectively, added: Theres an entire secondary market that can come from any breakthrough technology. This is only the first generation of GLP-1 drugs and therefore the first generation of secondary markets, observed McHugh, who said GLP-1 drugs are driving interest in products that solve for energy levels, nutrient deficiencies, and gut issues. They are also prompting renewed interest in protein quality as well as quantity, she claimed
Availability Disclaimer: Program availability varies by state and is not available in all 50 states
00967-0/asset/e600c3fc-c7b2-4bc5-adb8-0138decc3ad3/main.assets/gr3_lrg.jpg)
